A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Kallend et al., NCT04676867, NCT04676867, May 2021
Mortality -134% improvement lower risk ← → higher risk Ventilation -134% Oxygen therapy -139% Hospitalization -37% Dalcetrapib  Kallend et al.  EARLY TREATMENT RCT Is early treatment with dalcetrapib beneficial for COVID-19? Double-blind RCT 227 patients in Canada Trial underpowered to detect differences c19early.org Kallend et al., NCT04676867, May 2021 0 0.5 1 1.5 2+ RR
RCT 227 COVID-19 outpatients with symptom onset within 5 days, showing no signficiant benefits with dalcetrapib treatment.
Important missing comments or errors? Let us know.
risk of death, 134.2% higher, RR 2.34, p = 1.00, treatment 1 of 155 (0.6%), control 0 of 53 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 134.2% higher, RR 2.34, p = 1.00, treatment 1 of 155 (0.6%), control 0 of 53 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of oxygen therapy, 139.4% higher, RR 2.39, p = 0.68, treatment 7 of 155 (4.5%), control 1 of 53 (1.9%).
risk of hospitalization, 36.8% higher, RR 1.37, p = 1.00, treatment 8 of 155 (5.2%), control 2 of 53 (3.8%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kallend et al., 17 May 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, preprint, 1 author, trial NCT04676867 (history). Contact: dkallend@dalcorpharma.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org December 2025 Canada United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR Canada favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org December 2025 Canada United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Vietnam Peru Philippines China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria Canada favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0